Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis

International Journal of Cancer

Volumn 128, Issue 2, 2011, Pages 371-378

  Briesemeister, Dana ^a   Sommermeyer, Daniel ^b   Loddenkemper, Christoph ^c   Loew, Rainer ^d   Uckert, Wolfgang ^b,e   Blankenstein, Thomas ^a,b   Kammertoens, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c Charité Campus Benjamin Franklin Medical Center   (Germany)

^d BIONTECH AG   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

Author keywords

established tumors; interferon gamma; tumor microenvironment

Indexed keywords

CD146 ANTIGEN; DOXYCYCLINE; GAMMA INTERFERON; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; AUTOCRINE EFFECT; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; ENDOTHELIUM CELL; FEMALE; GENETIC TRANSFECTION; HYPERTRANSAMINASEMIA; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; INTERFERON INDUCTION; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THERAPY EFFECT; TUMOR CELL CULTURE; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR NECROSIS; TUMOR REJECTION; TUMOR VASCULARIZATION; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; GRAFT REJECTION; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NECROSIS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL;

EID: 78649605954     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25350     Document Type: Article

References (27)

1. Kammertoens T, Schuler T, Blankenstein T,. Immunotherapy: target the stroma to hit the tumor. Trends Mol Med 2005; 11: 225-31.
2. Blankenstein T,. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005; 17: 180-6.
3. Prevost-Blondel A, Neuenhahn M, Rawiel M, Pircher H,. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen. Eur J Immunol 2000; 30: 2507-15.
4. Platzer C, Richter G, Uberla K, Hock H, Diamantstein T, Blankenstein T,. Interleukin-4-mediated tumor suppression in nude mice involves interferon-gamma. Eur J Immunol 1992; 22: 1729-33.
5. Dighe AS, Richards E, Old LJ, Schreiber RD,. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1: 447-56.
6. Qin Z, Blankenstein T,. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12: 677-86.
7. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T,. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63: 4095-100.
8. Schuler T, Blankenstein T,. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol 2003; 170: 4427-31.
9. Girardi M, Oppenheim D, Glusac EJ, Filler R, Balmain A, Tigelaar RE, Hayday AC,. Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. J Invest Dermatol 2004; 122: 699-706.
10. Spiotto MT, Rowley DA, Schreiber H,. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10: 294-8.
11. Zhang B, Karrison T, Rowley DA, Schreiber H,. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008; 118: 1398-404.
12. Blohm U, Potthoff D, van der Kogel AJ, Pircher H,. Solid tumors "melt" from the inside after successful CD8 T cell attack. Eur J Immunol 2006; 36: 468-77.
13. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ,. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408-14.
14. Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008; 13: 507-18.
15. Sgadari C, Angiolillo AL, Tosato G,. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87: 3877-82.
16. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G,. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997; 89: 2635-43.
17. Loew R, Meyer Y, Kuehlcke K, Gama-Norton L, Wirth D, Hauser H, Stein S, Grez M, Thornhill S, Thrasher A, Baum C, Schambach A,. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration. Gene Ther 2009; 17: 272-80.
18. Sommermeyer D, Neudorfer J, Weinhold M, Leisegang M, Engels B, Noessner E, Heemskerk MH, Charo J, Schendel DJ, Blankenstein T, Bernhard H, Uckert W,. Designer T cells by T cell receptor replacement. Eur J Immunol 2006; 36: 3052-9.
19. Schrage A, Loddenkemper C, Erben U, Lauer U, Hausdorf G, Jungblut PR, Johnson J, Knolle PA, Zeitz M, Hamann A, Klugewitz K,. Murine CD146 is widely expressed on endothelial cells and is recognized by the monoclonal antibody ME-9F1. Histochem Cell Biol 2008; 129: 441-51.
20. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T,. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 1993; 90: 2774-8.
21. Hollenbaugh JA, Reome J, Dobrzanski M, Dutton RW,. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J Immunol 2004; 173: 1738-43.
22. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A,. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Can Urol Oncol Group N Engl J Med 1998; 338: 1265-71.
23. Brown TD, Koeller J, Beougher K, Golando J, Bonnem EM, Spiegel RJ, von Hoff DD,. A phase I clinical trial of recombinant DNA gamma interferon. J Clin Oncol 1987; 5: 790-8.
24. Schreiber K, Rowley DA, Riethmuller G, Schreiber H,. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am 2006; 20: 567-84.
25. Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H,. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res 2008; 68: 1563-71.
26. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T,. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 2001; 194: 1549-59.
27. Hengst JC, Mokyr MB, Dray S,. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. Cancer Res 1980; 40: 2135-41.